LYFE, Qiming lead $70m Series B round for Chinese biotech firm MediLink

LYFE, Qiming lead $70m Series B round for Chinese biotech firm MediLink

14 March, 2022

antibody-drug conjugates Lyfe Capital MediLink Therapeutics Qiming Venture Partners

Printed by Unregistered user on Sun, 21 Dec 2025 07:46:39 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Venture Capital

China's ZhenGe Biotech secures $100m in Series C round

Biotech firm BeiGene slides in Shanghai debut after $3.5b STAR Market IPO

Read more from Greater China

Chinese humanoid robot developer Galbot raises $300m at $3b valuation

‘Singapore washing’ gains pace as Chinese firms relocate to city-state